Form 4: Modular Medical COO Granted Options Contingent on FDA Clearance

Kevin Schmid, Chief Operating Officer of Modular Medical, Inc., was granted options to purchase common stock, contingent on FDA clearance of the company's initial pump product by December 31, 2024.

Summary

• On August 22, 2024, Kevin Schmid, the Chief Operating Officer of Modular Medical, Inc., was granted an option to purchase 24,400 shares of common stock at an exercise price of $1.71 per share.
• The options vest entirely if Modular Medical receives FDA 510(K) clearance for its initial pump product by December 31, 2024.
• If the FDA clearance is not received by this date, the options will not vest and will terminate on January 1, 2025.
• The options expire on August 22, 2034.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The granting of options is a standard practice, but the vesting condition introduces uncertainty related to FDA clearance.

Positives

• The granting of options to the COO aligns his interests with the company's success in obtaining FDA clearance.
• The vesting condition incentivizes the COO to work towards achieving FDA clearance by the specified deadline.

Negatives

• If FDA clearance is not obtained by December 31, 2024, the options will not vest, potentially impacting the COO's motivation.

Risks

• The company may not receive FDA clearance for its initial pump product by the specified deadline.
• Failure to obtain FDA clearance could negatively impact the company's stock price and future prospects.

Future Outlook

The vesting of the options is contingent on the company receiving FDA clearance for its initial pump product by December 31, 2024, which will be a key milestone for the company.

Industry Context

FDA clearance is a critical milestone for medical device companies like Modular Medical, and the granting of options tied to this milestone is a common practice to incentivize management.

Comparison to Industry Standards

• Option grants are a standard form of compensation for executives in publicly traded companies, particularly in the biotech and medical device industries.
• The vesting conditions tied to regulatory milestones like FDA clearance are also common, aligning management's interests with the company's success in navigating the regulatory process.
• Comparable companies in the medical device space, such as Insulet or Tandem Diabetes Care, also utilize stock options and other equity-based compensation to incentivize their executives.

Stakeholder Impact

• Shareholders: The potential for FDA clearance could positively impact the company's stock price.
• Employees: The granting of options to the COO could boost employee morale and motivation.
• Customers: Successful FDA clearance would allow the company to bring its initial pump product to market, benefiting patients.

Next Steps

• Modular Medical will need to obtain FDA 510(K) clearance for its initial pump product by December 31, 2024, for the options to vest.
• Investors should monitor the company's progress towards obtaining FDA clearance.

Key Dates